Reference : Usefulness of fluoxetine in obese non-insulin-dependent diabetics: a multicenter study.
Scientific journals : Article
Human health sciences : Pharmacy, pharmacology & toxicology
Human health sciences : Endocrinology, metabolism & nutrition
http://hdl.handle.net/2268/13862
Usefulness of fluoxetine in obese non-insulin-dependent diabetics: a multicenter study.
English
Daubresse, Jean-Claude [> > > >]
Kolanowski, J. [> > > >]
Krzentowski, G. [> > > >]
Kutnowski, M. [> > > >]
Scheen, André mailto [Université de Liège - ULiège > Département des sciences cliniques > Diabétologie, nutrition et maladie métaboliques - Médecine interne générale >]
Van Gaal, L. [> > > >]
1996
Obesity Research
North American Association for the Study of Obesity (NAASO)
4
4
391-6
Yes (verified by ORBi)
1071-7323
1550-8528
Silver Spring
MD
[en] Adolescent ; Adult ; Blood Glucose/metabolism ; Body Mass Index ; Diabetes Mellitus/drug therapy ; Diabetes Mellitus, Type 2/drug therapy ; Double-Blind Method ; Fluoxetine/adverse effects/therapeutic use ; Hemoglobin A, Glycosylated/metabolism ; Humans ; Insulin/blood ; Lipids/blood ; Middle Aged ; Obesity ; Placebos ; Triglycerides/blood ; Weight Loss
[en] Weight reduction is essential in the management of most non-insulin-dependent diabetics, but this therapeutical goal is difficult to obtain. In this double-blind parallel study, 82 non-insulin-dependent diabetics, moderately obese (BMI = 30 - 39 kg/m2), were given for an 8-week period either placebo (P) or fluoxetine (F), a specific serotonin reuptake inhibitor, in addition to their usual antidiabetic treatment. Thirty-nine of them received 60 mg fluoxetine a day and 43 were given the placebo. At admission, both groups had similar weight excess, metabolic control and serum lipid values. In comparison with the P-treated subjects, those treated with fluoxetine (F) lost more weight after 3 weeks (-1.9 vs. -0.7 kg, p < -0.0009) and after 8 weeks (-3.1 vs. -0.9 kg, p < 0.0007). Fasting blood glucose decreased in group F after 3 weeks (-1.5 vs -0.4 mmol/L, p < 0.003) and after 8 weeks (-1.7 vs. -0.02 mmol/L, p < 0.0004). HbAlc decreased from 8.5% to 7.7% in group F and from 8.6% to 8.3% in group P (p = 0.057). Mean triglyceride level was also reduced in group F after 8 weeks (p = 0.042). Fasting C-peptide did not change in either group, but fasting insulin values decreased in group F after 3 weeks (p < 0.02) and after 8 weeks (p < 0.05). The insulin/C-peptide molar ratio decreased significantly in group F after 3 weeks (p < 0.04) and after 8 weeks (p < 0.05) in comparison with group P. The drug was generally well tolerated and no major side effects were reported. In conclusion, the addition of fluoxetine to the usual oral hypoglycemic agent therapy might be beneficial in obese non-insulin-dependent diabetics, at least on a short-term basis.
http://hdl.handle.net/2268/13862

There is no file associated with this reference.

Bookmark and Share SFX Query

All documents in ORBi are protected by a user license.